Tarsus Pharmaceuticals, Inc.
TARS
Clasificación en acciones
#4581
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Precio por acción
$72.57
Capitalización bursátil
$3.40B
Cambio (1 día)
2.17%
Cambio (1 año)
2.47%
País
US
Comercio Tarsus Pharmaceuticals, Inc. (TARS)
Categoría
Healthcare
Ingresos de Tarsus Pharmaceuticals, Inc. (TARS)
Ingresos en Jun 2026 TTM: $606.33M
Según los últimos informes financieros de Tarsus Pharmaceuticals, Inc., los ingresos actuales de la empresa (TTM) son $606.33M. En 2023, la empresa obtuvo unos ingresos de $17.45M una disminución en comparación con los ingresos del año 2022, que fueron de $25.82M. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Tarsus Pharmaceuticals, Inc. desde 2018 hasta 2026
Ingresos al final de cada año
| Año | Ingresos | Cambiar |
|---|---|---|
| 2026 (TTM) | $606.33M | 231.41% |
| 2024 | $182.95M | 948.62% |
| 2023 | $17.45M | -32.42% |
| 2022 | $25.82M | -54.73% |
| 2021 | $57.03M | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
Ingresos de empresas similares o competidoras
| Empresa | Ingresos | Diferencia de ingresos | País |
|---|---|---|---|
| $12.62B | 1,982.08% |
US
|
|
| $2.23B | 267.46% |
US
|
|
| $15.74B | 2,496.66% |
AU
|
|
| $6.02B | 893.07% |
NL
|
|
| - | - |
CH
|
